HEALTHCARE
Oncology Fast Facts
Season 4
About This Season
Season 4 of Fast Facts Oncology is a three-part special that focuses on myelodysplastic syndromes. We are joined by experts Dr Zachariah DeFilipp, Dr Elizabeth Griffiths and Dr Courtney DiNardo.
All Episodes
Episode 3 - Perspectives on AML withCourtney DiNardo
This is the third episode in our series on myelodysplastic syndromes (MDS) which aims to update clinicians on the latest developments in their diagnosis and management.
In this episode, Dr. DiNardo discusses the missing pieces of MDS management, starting with the latest approvals in MDS treatment and how eligibility for clinical trials is assessed. She also touches on which impacts of transplantation or transformation to acute myeloid leukemia (AML) can be managed. She also touches on the cutting-edge genetic insights that might deliver on the promise of personalized medicine to MDS patients with the most challenging diagnoses.
Episode 2 - Real World Evidence in Myelodysplastic Syndromes with Elizabeth Griffiths
This is the second episode in our series on myelodysplastic syndromes (MDS) which aims to update clinicians on the latest developments in their diagnosis and management.
In this episode, Dr. Griffiths discusses what makes Real World Evidence and how it is obtained or archived, the risk stratification of MDS and what that means for gathering evidence, and bridging the gap between the best outcomes of clinical trials and the down-to-Earth results seen in daily clinical practice.
Episode 1 - Emerging Treatment Paradigms in Myelodysplastic Syndromes with Zachariah DeFilipp
This is the first episode in our series on myelodysplastic syndromes which aims to update clinicians on the latest developments in their diagnosis and management.
In this episode, Dr. DeFilipp outlines the current and upcoming treatments for myelodysplastic syndromes. He discusses doublet and triplet combinations that are moving the needle on disease management, including emerging therapies and combinations of hypomethylating agents. He also considers which underlying mutations pose the greatest challenges and/or provide the greatest opportunities for future research in the field.
About the Speakers
Zachariah DeFilipp, MD
Dr. DeFilipp is Director of Bone Marrow Transplant Clinical Research at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School. Dr. DeFilipp received his medical degree from Tel Aviv University’s Sackler School of Medicine in 2010. Following his internship and residency in internal medicine at the Western Pennsylvania Allegheny Health System in Pittsburgh, PA, he completed his fellowship in hematology and medical oncology at the Winship Cancer Institute of Emory University in Atlanta, GA. In 2016, Dr. DeFilipp joined the Blood and Marrow Transplant Program at the Massachusetts General Hospital Cancer Center. Dr. DeFilipp is actively involved in translational and clinical research initiatives to improve outcomes for patients undergoing autologous and allogeneic hematopoietic cell transplantation. He serves as principal investigator on multiple clinical trials for the Blood and Marrow Transplant Program at Massachusetts General Hospital.
Elizabeth Griffiths, MD
Dr. Griffiths is Director of the Myelodysplastic Syndromes (MDS) program at Roswell Park Comprehensive Cancer Center, recognized by The MDS Foundation as an MDS Center of Excellence. She is also an Associate Professor of Medicine at the State University of New York at Buffalo, and a faculty member of the Roswell Park Comprehensive Cancer Center-SUNY Buffalo graduate training programs in the departments of Pharmacology and Therapeutics, Translational Medicine and Immunology. Her research is focused on the mechanism of hypomethylating drugs (HMAs) in patients with myeloid cancer, specifically the contribution of the immune system to these responses. Dr. Griffiths and her team have examined how HMAs can cause re-expression of proteins in cancer cells that can be targeted by the immune system. She has authored/co-authored more than 50 peer-reviewed publications, and has been recognizes as on of the “Top Doctors of 2023” by Buffalo Spree magazine.
Courtney DiNardo, MD MSCE
Dr. DiNardo is an Associate Professor of Medicine and Clinical Researcher at The University of Texas MD Anderson Cancer Center in Houston, Texas. Her research focuses on prognostication and personalized therapeutics for patients with myeloid malignancies. Dr. DiNardo is the primary investigator of multiple novel IDH1 or IDH2-targeted therapeutic agents currently in clinical trials. Dr. DiNardo is also involved in the clinical development of the BCL2-inhibitor venetoclax (ABT-199) for myeloid malignancies. She is leading the study of venetoclax in combination with hypomethylating agent therapy for the treatment of newly diagnosed elderly AML patients. In addition, Dr. DiNardo’s clinical and research focus pertaining to hereditary cancer predisposition syndromes has led to the development of the MD Anderson Hereditary Hematologic Malignancy Clinic, which now provides clinical and research-based evaluation of underlying cancer predispositions and hereditary cancer syndromes in leukemia patients.
